Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung cancer is the leading cause of cancer-related death in men, with advanced stages remaining largely incurable despite chemotherapy advancements.
• Understanding the molecular mechanisms of lung carcinogenesis is crucial for identifying effective therapeutic targets.
• Cyclooxygenase-2 (COX-2), an inflammation factor, is frequently upregulated in various cancers, including lung cancer.

Purpose of the Study:

• To review the mechanism of action of COX-2 in cancer progression.
• To discuss the therapeutic applications of COX-2 inhibitors in lung cancer treatment.
• To summarize current clinical studies and future management strategies involving COX-2 inhibitors for lung cancer.

Main Methods:

• Literature review of studies on COX-2, lung carcinogenesis, and COX-2 inhibitors.
• Analysis of clinical trials investigating selective COX-2 inhibitors for lung cancer.
• Discussion of the role of inflammation in cancer progression.

Main Results:

• COX-2 is implicated in cancer progression, making it a potential therapeutic target.
• Selective COX-2 inhibitors, such as celecoxib, are being investigated for lung cancer treatment, with some showing feasibility and clinical activity.
• Existing COX-2 inhibitors have limitations due to risk factors, leading to cautious usage recommendations (e.g., low dosage or alternative therapies).

Conclusions:

• Selective COX-2 inhibitors show promise in lung cancer treatment, either as single agents or in combination therapies.
• Further clinical trials are essential to fully understand the role of these inhibitors in lung cancer prevention and treatment, and to assess their toxicity.
• Future management strategies may involve optimized use of COX-2 inhibitors to overcome therapeutic limitations in lung cancer.